Data from a recent clinical trial suggested that inhibitors of mTOR and glutamine, such as everolimus and telaglenastat, exerted a therapeutic effect on NSCLC patients with STK11/LKB1 mutations (Ndembe et al., 2022; Sumbly and Landry, 2022). This evidence concerns the gene STK11 and non-small cell lung carcinoma.